Free Trial
NASDAQ:TELO

Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis

Telomir Pharmaceuticals logo
$1.61 -0.32 (-16.58%)
As of 11:31 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Telomir Pharmaceuticals Stock (NASDAQ:TELO)

Advanced

Key Stats

Today's Range
$1.60
$1.82
50-Day Range
$1.18
$1.93
52-Week Range
$1.12
$7.08
Volume
1.94 million shs
Average Volume
1.96 million shs
Market Capitalization
$51.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Moderate Buy

Company Overview

Telomir Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

TELO MarketRank™: 

Telomir Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat, and ranked 489th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Telomir Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    Telomir Pharmaceuticals has a consensus price target of $15.00, representing about 805.8% upside from its current price of $1.66.

  • Amount of Analyst Coverage

    Telomir Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Telomir Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Telomir Pharmaceuticals are expected to grow in the coming year, from ($0.40) to ($0.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Telomir Pharmaceuticals is -3.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Telomir Pharmaceuticals is -3.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Telomir Pharmaceuticals has a P/B Ratio of 82.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Telomir Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    11.26% of the float of Telomir Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Telomir Pharmaceuticals has recently decreased by 41.85%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Telomir Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Telomir Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.26% of the float of Telomir Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Telomir Pharmaceuticals has recently decreased by 41.85%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Telomir Pharmaceuticals has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Telomir Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    26 people have searched for TELO on MarketBeat in the last 30 days. This is an increase of 189% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Telomir Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
Receive TELO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telomir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TELO Stock News Headlines

BlackRock’s Shocking Crypto Move
BlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging crypto — now called “Wall Street’s preferred choice” — with tech giants like Microsoft, Google, and Amazon already using it.tc pixel
See More Headlines

TELO Stock Analysis - Frequently Asked Questions

Telomir Pharmaceuticals' stock was trading at $4.12 on January 1st, 2025. Since then, TELO shares have decreased by 59.8% and is now trading at $1.6560.

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) posted its earnings results on Thursday, August, 14th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.09.

Telomir Pharmaceuticals (TELO) raised $7 million in an IPO on Friday, February 9th 2024. The company issued 1,000,000 shares at a price of $7.00 per share. Kingswood Investments served as the underwriter for the IPO.

Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/14/2025
Today
10/09/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TELO
Previous Symbol
NASDAQ:TELO
CIK
1971532
Fax
N/A
Employees
1
Year Founded
N/A

Price Target and Rating

High Price Target
$15.00
Low Price Target
$15.00
Potential Upside/Downside
+677.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$16.53 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-4,595.08%
Return on Assets
-1,750.91%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.39
Quick Ratio
2.39

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.02 per share
Price / Book
96.50

Miscellaneous

Outstanding Shares
32,280,000
Free Float
N/A
Market Cap
$62.30 million
Optionable
N/A
Beta
-0.60
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:TELO) was last updated on 10/10/2025 by MarketBeat.com Staff
From Our Partners